239 related articles for article (PubMed ID: 20704358)
1. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?
Hanif M; Henke H; Meier SM; Martic S; Labib M; Kandioller W; Jakupec MA; Arion VB; Kraatz HB; Keppler BK; Hartinger CG
Inorg Chem; 2010 Sep; 49(17):7953-63. PubMed ID: 20704358
[TBL] [Abstract][Full Text] [Related]
2. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
3. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
4. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
5. Organometallic ruthenium and osmium compounds of pyridin-2- and -4-ones as potential anticancer agents.
Henke H; Kandioller W; Hanif M; Keppler BK; Hartinger CG
Chem Biodivers; 2012 Sep; 9(9):1718-27. PubMed ID: 22976964
[TBL] [Abstract][Full Text] [Related]
6. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
[TBL] [Abstract][Full Text] [Related]
7. Antimalarial activity of ruthenium(II) and osmium(II) arene complexes with mono- and bidentate chloroquine analogue ligands.
Ekengard E; Glans L; Cassells I; Fogeron T; Govender P; Stringer T; Chellan P; Lisensky GC; Hersh WH; Doverbratt I; Lidin S; de Kock C; Smith PJ; Smith GS; Nordlander E
Dalton Trans; 2015 Nov; 44(44):19314-29. PubMed ID: 26491831
[TBL] [Abstract][Full Text] [Related]
8. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
[TBL] [Abstract][Full Text] [Related]
9. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands.
Kurzwernhart A; Kandioller W; Bächler S; Bartel C; Martic S; Buczkowska M; Mühlgassner G; Jakupec MA; Kraatz HB; Bednarski PJ; Arion VB; Marko D; Keppler BK; Hartinger CG
J Med Chem; 2012 Dec; 55(23):10512-22. PubMed ID: 23134291
[TBL] [Abstract][Full Text] [Related]
11. Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids.
Filak LK; Kalinowski DS; Bauer TJ; Richardson DR; Arion VB
Inorg Chem; 2014 Jul; 53(13):6934-43. PubMed ID: 24927493
[TBL] [Abstract][Full Text] [Related]
12. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
[TBL] [Abstract][Full Text] [Related]
13. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
14. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
Fernández R; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Chemistry; 2004 Oct; 10(20):5173-9. PubMed ID: 15372674
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and antitumor activity of water-soluble (arene)ruthenium(II) derivatives of 1,3-dimethyl-4-acylpyrazolon-5-ato ligands. First example of Ru(arene)(ligand) antitumor species involving simultaneous Ru-N7(guanine) bonding and ligand intercalation to DNA.
Caruso F; Monti E; Matthews J; Rossi M; Gariboldi MB; Pettinari C; Pettinari R; Marchetti F
Inorg Chem; 2014 Apr; 53(7):3668-77. PubMed ID: 24611608
[TBL] [Abstract][Full Text] [Related]
16. Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins.
Meier SM; Hanif M; Kandioller W; Keppler BK; Hartinger CG
J Inorg Biochem; 2012 Mar; 108():91-5. PubMed ID: 22420927
[TBL] [Abstract][Full Text] [Related]
17. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
18. Ligand-based neutral ruthenium(II) arene complex: selective anticancer action.
Wu CH; Wu DH; Liu X; Guoyiqibayi G; Guo DD; Lv G; Wang XM; Yan H; Jiang H; Lu ZH
Inorg Chem; 2009 Mar; 48(6):2352-4. PubMed ID: 19220049
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium(II)-arene complexes with functionalized pyridines: synthesis, characterization and cytotoxic activity.
Grgurić-Sipka S; Ivanović I; Rakić G; Todorović N; Gligorijević N; Radulović S; Arion VB; Keppler BK; Tesić ZLj
Eur J Med Chem; 2010 Mar; 45(3):1051-8. PubMed ID: 20053483
[TBL] [Abstract][Full Text] [Related]
20. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity.
Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E
Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
